David Rizzieri, MD, Oncology, Durham, NC, Duke University Hospital

DavidRizzieriMD

Oncology Durham, NC

Professor, Medicine, Duke University School of Medicine Chief, Section of Hematologic Malignancies Assistant Director for Clinical Research, Division of Cellular Therapy and Hematologic Malignancies

Dr. Rizzieri is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Rizzieri's full profile

Already have an account?

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Hematology/Oncology, 1994 - 1997
  • University of Rochester
    University of RochesterResidency, Internal Medicine, 1991 - 1994
  • University of Rochester School of Medicine and Dentistry
    University of Rochester School of Medicine and DentistryClass of 1991
  • Hobart CollegeBS, General Biology, Summa Cum Laude, 1983 - 1987

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 1997 - 2021
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
  • Elected Member The American Society for Clinical Investigation, 2009
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • MDS: unraveling the mystery  
    Rizzieri DA, Blood, 12/1/2013
  • The genetic landscape of mutations in Burkitt lymphoma  
    Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WW, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers CR, ..., Nat Genet, 11/1/2012
  • Phase II Study of Cenersen, an Antisense Inhibitor of p53, in Combination with Fludarabine, Cyclophosphamide, and Rituximab for High Risk CLL  
    Lanasa MC, Davis PH, Datto M, Li Z, Gockerman JP, Moore JO, Decastro CM, Friedman DR, Diehl LF, Rehder C, Cook H, Daugherty FJ, Matta KM, Weinberg JB, Rizzieri D, Leuk Lymphoma, 2/1/2012
  • Join now to see all

Abstracts/Posters

  • Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart¬ Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
    David A. Rizzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic ...
    David A. Rizzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • A Phase I Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Blastic Plasmacytoid Dendriti...
    David A. Rizzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • ET190L1-ARTEMISTM T Cell Therapy Results in Durable Disease Remissions with No Cytokine Release Syndrome or Neurotoxicity in Patients with Relapsed and Refractory B-Ce... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • OncLive® Presents State of the Science Summit™ on Hematologic Malignancies
    OncLive® Presents State of the Science Summit™ on Hematologic MalignanciesApril 25th, 2019
  • Staley Helps Sister Battle Leukemia, Seeks More Black Donors
    Staley Helps Sister Battle Leukemia, Seeks More Black DonorsMarch 19th, 2021

Professional Memberships

Hospital Affiliations